GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announces the success of its previously announced capital increase. The transaction was led by Arix Bioscience plc (LON: ARIX), Invus and Sofinnova Partners.
The Company has issued 5,954,650 new ordinary shares with a nominal value of €0.025 each (the “New Shares“), for total gross proceeds of approximately €25 million by means of an accelerated bookbuilding process to the benefit of categories of persons (the “Reserved Offering“). The book was oversubscribed, based on demand from new and existing investors.
The Jones Day team was led by Linda Hesse and also included Florent Bouyer.
